BBIO in the 13F filings
Bridgebio Pharma Inc · CUSIP 10806X102
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 22 Jan 2026
- Managers listing it
- 33
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 14 listed it in both
- Shares listed
- 61,608,413
- combined, among listed positions
- Reported value
- $4.7bn
- combined, at the quarter end
Among the 92 comparable managers: 22 buyers (opened or added shares) and 12 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +6,175,914.
Managers listing BBIO in Q4 2025
33 of 33 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 3,828,746 shares now+2,261,181
- Janus Henderson Group Ltdexisting position · 11,000,457 shares now+2,259,378
- Wellington Management Group LLPexisting position · 2,348,731 shares now+1,329,537
- Invesco Ltdexisting position · 4,831,305 shares now+902,648
- Farallon Capital Management LLCexisting position · 8,998,463 shares now+806,463
Reductions
- Viking Global Investors LPexisting position · 14,393,934 shares now-1,583,915
- Balyasny Asset Management LLCexisting position · 234,389 shares now-780,288
- Two Sigma Investments LPexisting position · 1,947,047 shares now-381,894
- Jane Street Group LLCexisting position · 341,795 shares now-292,091
- AllianceBernstein LPexisting position · 2,050,746 shares now-277,969
New positions and exits
New (5)
Exited (1)
- Renaissance Technologies LLCwas $17m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2019 | 2 | $719m | n.a. | n.a. |
| Q3 2019 | 1 | $572m | n.a. | n.a. |
| Q4 2019 | 2 | $1.0bn | n.a. | n.a. |
| Q1 2020 | 3 | $824m | n.a. | n.a. |
| Q2 2020 | 4 | $926m | n.a. | n.a. |
| Q3 2020 | 4 | $1.1bn | n.a. | n.a. |
| Q4 2020 | 5 | $2.0bn | n.a. | n.a. |
| Q1 2021 | 5 | $1.9bn | n.a. | n.a. |
| Q2 2021 | 5 | $1.8bn | n.a. | n.a. |
| Q3 2021 | 4 | $1.4bn | n.a. | n.a. |
| Q4 2021 | 2 | $452m | n.a. | n.a. |
| Q1 2022 | 2 | $276m | n.a. | n.a. |
| Q2 2022 | 2 | $246m | n.a. | n.a. |
| Q3 2022 | 3 | $271m | n.a. | n.a. |
| Q4 2022 | 2 | $204m | n.a. | n.a. |
| Q1 2023 | 4 | $477m | n.a. | n.a. |
| Q2 2023 | 2 | $463m | n.a. | n.a. |
| Q3 2023 | 9 | $898m | n.a. | n.a. |
| Q4 2023 | 9 | $1.3bn | 1 | 7 |
| Q1 2024 | 7 | $1.1bn | 5 | 2 |
| Q2 2024 | 4 | $826m | 2 | 0 |
| Q3 2024 | 8 | $927m | 7 | 0 |
| Q4 2024 | 7 | $1.2bn | 4 | 3 |
| Q1 2025 | 9 | $1.6bn | 6 | 3 |
| Q2 2025 | 15 | $2.3bn | 11 | 4 |
| Q3 2025 | 14 | $2.3bn | 5 | 9 |
| Q4 2025 | 18 | $4.3bn | 22 | 12 |
| Q1 2026 | 20 | $4.4bn | 20 | 14 |
| Q2 2026 | 18 | $4.5bn | 24 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
BBIO and LLY →BBIO and JNJ →BBIO and VRTX →Choose a stock to compare with BBIO →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own BBIO, latest filings →Back to the 13F Explorer →